Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UK Glaucoma Treatment Study
2006-000653-22Phase 4Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of latanoprost in open-angle glaucoma (OAG), normal tension glaucoma (NTG) and pseudoexfoliation glaucoma (PXG), sponsored by Moorfields Eye Hospital. Primary endpoint: Visual field progression within 18 months. Started Aug 2019; status: completed.
02
Drugs
latanoprost
03
Conditions
open-angle glaucoma (OAG)normal tension glaucoma (NTG)pseudoexfoliation glaucoma (PXG)
Beyond the preview
Go deeper on 2006-000653-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000653-22.